L Andersson1, K Blennow, D Fuchs, B Svennerholm, M Gisslén. 1. Institute of Internal Medicine, Department of Infectious Diseases, Göteborg University, Sahlgrenska University Hospital, S-416 85, Göteborg, Sweden. lars-magnus.andersson@medfak.gu.se
Abstract
OBJECTIVES: Assessment of cerebrospinal fluid (CSF) levels of protein tau in human immunodeficiency virus type 1 (HIV-1) infection. MATERIAL AND METHODS: CSF tau levels were analyzed in 52 HIV-1-infected patients, 37 of whom had no neurological symptoms, eight had aquired immunodeficiency syndrome (AIDS) dementia complex (ADC), and seven had AIDS with other neurological complications. RESULTS: A significantly higher mean CSF tau concentration was found in patients with ADC (380 pg/ml) compared with patients with neuroasymptomatic HIV-1 infection (120 pg/ml, P<0.01) and HIV-negative controls (150 pg/ml, P<0.05). No difference in CSF tau levels was found between patients with ADC and patients with AIDS with other neurological complications. CONCLUSION: CSF tau might be used as a biochemical marker for axonal degeneration and might be of use to identify HIV-1-infected patients with ADC and other neurological complications, but it cannot discriminate between ADC and other neurological complications in HIV-1-infection.
OBJECTIVES: Assessment of cerebrospinal fluid (CSF) levels of protein tau in human immunodeficiency virus type 1 (HIV-1) infection. MATERIAL AND METHODS: CSF tau levels were analyzed in 52 HIV-1-infectedpatients, 37 of whom had no neurological symptoms, eight had aquired immunodeficiency syndrome (AIDS) dementia complex (ADC), and seven had AIDS with other neurological complications. RESULTS: A significantly higher mean CSF tau concentration was found in patients with ADC (380 pg/ml) compared with patients with neuroasymptomatic HIV-1 infection (120 pg/ml, P<0.01) and HIV-negative controls (150 pg/ml, P<0.05). No difference in CSF tau levels was found between patients with ADC and patients with AIDS with other neurological complications. CONCLUSION: CSF tau might be used as a biochemical marker for axonal degeneration and might be of use to identify HIV-1-infectedpatients with ADC and other neurological complications, but it cannot discriminate between ADC and other neurological complications in HIV-1-infection.
Authors: Jan J Krut; Richard W Price; Henrik Zetterberg; Dietmar Fuchs; Lars Hagberg; Aylin Yilmaz; Paola Cinque; Staffan Nilsson; Magnus Gisslén Journal: Virulence Date: 2016-07-19 Impact factor: 5.882
Authors: Magnus Gisslén; Jan Krut; Ulf Andreasson; Kaj Blennow; Paola Cinque; Bruce J Brew; Serena Spudich; Lars Hagberg; Lars Rosengren; Richard W Price; Henrik Zetterberg Journal: BMC Neurol Date: 2009-12-22 Impact factor: 2.474
Authors: Albert M Anderson; David Croteau; Ronald J Ellis; Debra Rosario; Michael Potter; Gilles J Guillemin; Bruce J Brew; Steven Paul Woods; Scott L Letendre Journal: J Neuroimmunol Date: 2018-03-18 Impact factor: 3.478
Authors: Sérgio Monteiro de Almeida; Clea E Ribeiro; Indianara Rotta; Mauro Piovesan; Bin Tang; Florin Vaida; Sonia Mara Raboni; Scott Letendre; Michael Potter; Meire S Batistela Fernandes; Ronald J Ellis Journal: J Neurovirol Date: 2017-10-23 Impact factor: 2.643
Authors: Steven Paul Woods; Erin E Morgan; Jennifer Marquie-Beck; Catherine L Carey; Igor Grant; Scott L Letendre Journal: Cogn Behav Neurol Date: 2006-12 Impact factor: 1.600
Authors: Jerel Adam Fields; Wilmar Dumaop; Leslie Crews; Anthony Adame; Brian Spencer; Jeff Metcalf; Johnny He; Edward Rockenstein; Eliezer Masliah Journal: Curr HIV Res Date: 2015 Impact factor: 1.581
Authors: Michael J Peluso; Dieter J Meyerhoff; Richard W Price; Julia Peterson; Evelyn Lee; Andrew C Young; Rudy Walter; Dietmar Fuchs; Bruce J Brew; Paola Cinque; Kevin Robertson; Lars Hagberg; Henrik Zetterberg; Magnus Gisslén; Serena Spudich Journal: J Infect Dis Date: 2013-03-04 Impact factor: 5.226